Abstract
This study characterizes the pharmacokinetic-pharmacodynamic (PK-PD) relationships of the cardiovascular, EEG, hypnotic and ventilatory effects of the alpha-2 adrenergic agonist dexmedetomidine in rats. Dexmedetomidine was administered by a single rapid infusion (n = 6) and by an infusion regimen of gradually increasing rate (n = 8). HR, mean arterial pressure (MAP) and EEG signals were recorded continuously, as was the time at which the rats woke up spontaneously from drug-induced sleep, a measure of hypnosis. Arterial concentrations of dexmedetomidine and blood gases were determined regularly. A sigmoidal Emaxmodel was used to describe the HR, MAP and EEG concentration-effect relationships, with the EEG effect (activity in 0.5–3.5-Hz frequency band) linked to an effect-site model. The PK of dexmedetomidine could be described by a two-compartment model, with similar PK parameters for both infusion regimens. Plasma protein binding was 84.1[0.7]%. Because of complex cardiovascular homeostatic reflex mechanisms, HR and MAP could only be analyzed during gradually increasing infusions. The maximal decrease in HR was 35(2)%, and the maximal increase in MAP was 37(2)%. For both infusion regimens, similar PD parameters were found for the EEG and the hypnotic measure. These data suggest the absence of active metabolites or tolerance of the EEG and hypnotic effects. Judging on the basis of concentrations of dexmedetomidine (mean (S.E.M.)), HR decrease was the most sensitive response [EC50 of 0.65(0.09) ng/ml], followed by increase in MAP [EC50 of 2.01(0.14) ng/ml], change in EEG activity [EC50 of 2.24(0.16) ng/ml] and the hypnotic measure [Cwake-up of 2.64(0.10) ng/ml]. Ventilatory effects were minor.
Footnotes
-
Send reprint requests to: Cornelis J.J.G. Bol, M.Sc., Department of Clinical Pharmacokinetics, Janssen Pharmaceutica, B-2340 Beerse, Belgium.
-
↵1 This research was conducted at the Department of Anesthesiology, Stanford University School of Medicine, Stanford, CA. The work was supported in part by National Institutes of Health Shannon award GM-51309 and National Institute on Aging grant RO1-04594.
-
↵2 Present address: Janssen Pharmaceutica, Beerse, Belgium.
-
↵3 Present address: Pharsight Corporation, Palo Alto, CA.
- Abbreviations:
- MAP
- mean arterial pressure
- PK
- pharmacokinetic
- PD
- pharmacodynamic
- bpm
- beats per minute
- Received March 17, 1997.
- Accepted August 22, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|